What is Blaze Bioscience?
Blaze Bioscience operates at the intersection of advanced biotechnology and surgical precision, focusing primarily on the development of innovative solutions for cancer detection and removal. The company's core value proposition centers on its proprietary Tumor Paint technology, a molecular imaging agent designed to illuminate cancerous tissue in real-time. When integrated with the CANVAS imaging system, this platform provides surgeons with unprecedented visual clarity, significantly enhancing the accuracy of tumor resection. By targeting high-stakes procedures, such as pediatric brain cancer surgery, Blaze Bioscience addresses a critical unmet need in the healthcare market. The firm's commitment to improving patient prognosis through technological sensitivity and reliability positions it as a pivotal player in the evolving landscape of precision medicine and intraoperative diagnostics.
How much funding has Blaze Bioscience raised?
Blaze Bioscience has raised a total of $17M across 7 funding rounds:
Debt
$725K
Series A
$5M
Series B
$9M
Debt
$991K
Debt
$554K
Debt
$350K
Debt
$421K
Debt (2011): $725K, investors not publicly disclosed
Series A (2012): $5M, investors not publicly disclosed
Series B (2013): $9M, investors not publicly disclosed
Debt (2015): $991K, investors not publicly disclosed
Debt (2017): $554K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Debt (2021): $421K led by PPP
Key Investors in Blaze Bioscience
PPP
Public-Private Partnership
Undisclosed Investor
A strategic partner contributing to the equity-based growth rounds essential for the advancement of proprietary biotechnology platforms.
Undisclosed Investor
An undisclosed investor participating in the funding round to bolster the company's long-term research and development capabilities.
What's next for Blaze Bioscience?
Looking ahead, the strategic deployment of this capital will likely focus on scaling the commercial infrastructure required to support the widespread adoption of the CANVAS imaging system. As the company transitions from clinical validation to broader market penetration, management is expected to prioritize regulatory milestones and the expansion of its intellectual property portfolio. The recent funding context suggests a shift toward operational maturity, where the focus will be on optimizing supply chain logistics and fostering partnerships with leading academic medical centers. By maintaining its focus on high-precision oncology tools, Blaze Bioscience is poised to capture significant market share, ultimately setting a new standard for surgical intervention and patient care in the oncology space.
See full Blaze Bioscience company page
